[1] Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J]. Cancer Sci,2018,109(4):1207-1219.

[2] Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1[J]. Gene ,2018,654:77-86.

[3] Safety,pharmacokinetics,and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor,in patients with advanced refractory solid tumors[J]. J Hematol Oncol ,2016,9(1):105.

[4] Third-line treatment: a randomized, double-blind, placebo-controlled phase Ⅲ ALTER-0303 study-efficacy and safety of anlotinib treatment in patients with refractory advanced NSCLC[R]. 2017 ASCO,abs 9053.

[5] Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)[J]. Br J Cancer 2018,118(5):654-661.6.

[6] Efficiency of Anlotinib as 3rd line treatment in patients with diferent EGFR gene status, an exploration subgroup analysis of ALTER 0303 trial. 2017 WCLC,P3.03-006.

[7] Subgroup analysis of histology in ALTER0303: Anlotinib hydrochloride as 3rd line and further line treat- ment in refractory advanced NSCLC patients (pts). 2018 ASCO,abs 9080.

[8] Subgroup analysis of elderly patients (pts) in ALTER0303: Anlotinib hydrochloride as 3rd line and further line treatment in refractory advanced NSCLC pts from a randomized,double-blind,place- bo-controlled Phase III ALTER0303 trial. 2018,ASCO,abs e21181.

[9] Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial[J]. JAMA Oncol, 2018,4(11):1569-1575.

[10] Anlotinib as third-line or further-line treatment in relapsed SCLC: a multicentre, randomized, double-blind phase 2 trial. 2018,WCLC,OA 13.03.

[11] Phase II study of anlotinib for treatment of advanced soft tissues sarcomas. 2016,ASCO,abs 11005.

[12] Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma[J]. Clin Cancer Res,2018,24(21):5233-5238.

[13] Anlotinib for metastasis soft tissue sarcoma: A randomized, double-blind, placebo-controlled and multi-centered clinical trial. 2018 ASCO,abs 11503.

[14] Evaluation of hypertension and hand-foot syndrome as marker of anlotinib efficacy in advanced soft tissue sarcoma. 2018 ESMO,1633P.

[15] Efficacy of anlotinib in advanced soft tissue sarcoma by prior lines of the therapy, age and dose modification. 2018 ESMO,1630P.

[16] Phase II study of anlotinib for treatment of advanced medullary thyroid carcinoma. 2016 ASCO, abs 6015.

[17]  Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer. Thyroid ,2018,28(11):1455-1461.

[18] Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial. 2016,ASCO,abs 4565.

[19] Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: Preliminary results from a multicenter, phase II trial. 2016 ASCO,abs e16082.

[20] Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): a randomized, double-blind, multicenter phase II trial.2019,ASCOGI,abs 95.